Effect of calcium phosphate and vitamin D3supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron

Trautvetter, Ulrike; Neef, Nadja; Leiterer, Matthias; Kiehntopf, Michael; Kratzsch, Jürgen; Jahreis, Gerhard

doi:10.1186/1475-2891-13-6

Cited by 36 publications

(44 citation statements)

References 31 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our analysis was observational, the null findings are consistent with those from several prospective trials of vitamin D and/or calcium supplementation [31–33], which evaluated changes in bone remodeling biomarkers after intervention. The lack of an impact of supplementation on bone biomarkers might be due to the tight control of 1,25α-dihydroxyvitamin D levels, the active vitamin D metabolite in calcium homeostasis, which may be in a normal range even in individuals with vitamin D deficiency [34].…”

Section: Discussionsupporting

confidence: 82%

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

Yao

Zhang

Tang

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients’ demographic, lifestyle, clinical tumor characteristics, as well as bone health history. The presence of bone metastases, prior bisphosphonate (BP) treatment and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics did not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. These findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.

show abstract

Section: Discussionsupporting

confidence: 82%

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

Yao

Zhang

Tang

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Cholecalciferol was the main form of vitamin D that were supplemented in these studies. The duration of supplementation with vitamin D also varied from 3 h to 6 months [40][41][42][43][44][45][46][47][48][49][50][51][52][53].…”

Section: Study Characteristicsmentioning

confidence: 99%

The effect of vitamin D supplementation on hemoglobin concentration: a systematic review and meta-analysis

Arabi

Ranjbar

Bahrami

et al. 2020

Nutr J

View full text Add to dashboard Cite

Aims: The purpose of this review was to investigate the effect of vitamin D supplements on hemoglobin concentration in subjects aged 17.5-68 years old; using randomized controlled trials (RCTs). Methods: Relevant RCT studies were identified from January 2000 to January 2019 by using MeSH terms in PubMed, Embase, Cochrane Library, Clinical trials, Scopus databases and gray literature. The studies were reviewed systematically, and quality assessments were evaluated by the guidelines of the Cochrane risk of bias. The effect of vitamin D supplements (n = 14) on hemoglobin concentration was considered as primary outcome, while its effects on the levels of ferritin, transferrin saturation and iron status were derived as secondary outcomes. In total, 1385 subjects with age range of 17.5 to 68 years old were examined for 3 h to 6 months; Mean (standard deviation) or median interquartile changes in the hemoglobin concentration in each treatment group was recorded for metaanalysis. Results: Fourteen RCTs met the inclusion criteria. Current study findings propose that vitamin D supplementation leads to a non-significant reduction in hemoglobin levels in subjects (17.

show abstract

“…In studies involving young Caucasian adults with marginal vitamin D deficiency, no beneficial effects of vitamin D on bone markers have been observed (Barnes et al, 2006, Seamans et al, 2010, Aloia et al, 2010, Trautvetter et al, 2014). …”

Section: Discussionmentioning

confidence: 99%

Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway

et al. 2015

View full text Add to dashboard Cite

ObjectiveVitamin D is essential for the maintenance of calcium homeostasis and bone mineralization; and low serum 25-hydroxyvitamin D (s-25-(OH)D) concentrations are associated with increased bone turnover. However, there is a lack of randomized controlled trials that have investigated the effect of vitamin D treatment on bone turnover in immigrant populations. We aimed to investigate the effect of 16-week daily vitamin D3 supplementation on bone formation marker serum procollagen type 1 amino-terminal propeptide (P1NP) and bone resorption marker C-terminal crosslinked telopeptide of type I collagen (CTX).DesignDouble-blind, randomized, placebo-controlled trial.SettingImmigrant community centers in Oslo, Norway.Participants251 healthy adults aged 18–50 years with a non-Western immigrant background were recruited.Intervention16 weeks of daily oral supplementation with either 10 μg vitamin D3, 25 μg vitamin D3, or placebo.Main outcome measuresDifference in change during the 16-week intervention between the intervention groups combined (10 or 25 μg of vitamin D3/day) and placebo, in serum P1NP and serum CTX.ResultsA total of 214 (85%) participants completed the study. S-25-(OH)D increased from 29 nmol/L at baseline to 49 nmol/L in the intervention group with no significant change in the placebo group. However, there was no difference in change of serum P1NP (mean difference: − 1.2 μg/L (95% CI: − 5.4, 2.9, P = 0.6)) and serum CTX (mean difference: − 0.005 μg/L (95% CI: − 0.03, 0.02, P = 0.7)) between those receiving vitamin D3 supplementation compared with placebo. The plasma PTH had decreased by a mean of − 1.97 pmol/L (95% CI: − 2.7, − 1.3, P < 0.0001) in the vitamin D3 group compared to placebo.ConclusionsSupplementation with 10 or 25 μg oral vitamin D3 during winter and spring for 16 weeks did not significantly affect serum P1NP and serum CTX, despite increasing s-25(OH)D and decreasing PTH in a healthy immigrant population with low baseline vitamin D status.Trial registration number: NCT01263288.

show abstract

Effect of calcium phosphate and vitamin D3supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron

Cited by 36 publications

References 31 publications

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

The effect of vitamin D supplementation on hemoglobin concentration: a systematic review and meta-analysis

Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway

Contact Info

Product

Resources

About